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a  b  s  t  r  a  c  t
In the  absence  of speciﬁc  metabolic  disorders,  predictors  of  response  to  ketogenic  dietary  therapies  (KDT)
are  unknown.  We  aimed  to determine  whether  variants  in  established  candidate  genes  KCNJ11  and  BAD
inﬂuence  response  to  KDT.
We sequenced  KCNJ11  and  BAD  in  individuals  without  previously-known  glucose  transporter  type
1 deﬁciency  syndrome  or other  metabolic  disorders,  who  received  KDT  for epilepsy.  Hospital  records
were  used  to obtain  demographic  and  clinical  data.  Two  response  phenotypes  were  used:  ≥50% seizure
reduction  and  seizure-freedom  at 3-month  follow-up.  Case/control  association  tests  were  conducted
with  KCNJ11  and BAD  variants  with  minor  allele  frequency  (MAF)  > 0.01,  using  PLINK.  Response  to  KDT
in  individuals  with  variants  with  MAF  < 0.01  was  evaluated.
303 Individuals  had  KCNJ11  and  246  individuals  had  BAD  sequencing  data  and  diet response  data.  Six
SNPs  in  KCNJ11  and  two  in BAD  had  MAF  >  0.01.  Eight  variants  in  KCNJ11  and  seven  in BAD  (of  which  three
were  previously-unreported)  had  MAF  <  0.01.
No  signiﬁcant  results  were  obtained  from  association  analyses,  with  either  KDT response  phenotype.
P-values  were  similar  when  accounting  for ethnicity  using  a stratiﬁed  Cochran–Mantel–Haenszel  test.There  did not  seem  to be a consistent  effect  of  rare variants  on  response  to  KDT, although  the cohort
size  was  too  small  to assess  sig
Common  variants  in  KCNJ11
with  80%  power,  association  fr
needed  to detect  associations  
Abbreviations: KDT, ketogenic dietary therapies; SNP, single nucleotide polymorphism
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 and  BAD  do  not predict  response  to KDT for epilepsy.  We  can  exclude,
om  variants  with  a MAF  of  >0.05  and  effect  size  >3. A larger  sample  size  is
from  rare variants  or those  with  smaller  effect  sizes.
© 2015  Elsevier  B.V.  All  rights  reserved.
; MAF, minor allele frequency; CMH, Cochran–Mantel–Haenszel.
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Ketogenic dietary therapies (KDT) can be an effective treatment
or people with drug-resistant epilepsy (Henderson et al., 2006;
eene, 2006; Neal et al., 2008; Payne et al., 2011) and are the
reatment of choice for epilepsy associated with the genetic condi-
ions glucose transporter type 1 deﬁciency syndrome and pyruvate
ehydrogenase complex deﬁciency (Kossoff et al., 2009).
In the absence of speciﬁc metabolic disorders, predictors of
esponse to KDT are unknown (Schoeler et al., 2013). Certain epilep-
ies, many of which are caused by single gene mutations, may
espond well to KDT (Kossoff et al., 2009; Nangia et al., 2012;
hammongkol et al., 2012), although further evidence is needed
hat epilepsies of different aetiologies respond differently to KDT.
train-speciﬁc responsiveness to KDT in terms of seizure threshold
as been shown in mice (Dutton and Escayg, 2008). From animal
odels, two genes have been highlighted as candidates implicated
n the antiepileptic mechanisms of KDT (Giménez-Cassina et al.,
012): KCNJ11,  which encodes the Kir6.2 pore-forming subunit of
ATP channels, and BAD, which encodes the minimal death domain
H3-only protein and also has a metabolic role (Danial et al., 2003,
008).
BadS155A (from mice bearing a non-phosphorylatable knock-in
llele of BAD) and Bad−/− cortical neurons and astrocytes exhib-
ted increased mitochondrial utilisation of -hydroxybutyrate
nd decreased utilisation of glucose, compared with wild types
Giménez-Cassina et al., 2012). These changes in energy substrate
tilisation are reminiscent of the response to fasting or KDT.
adS155A and Bad−/− mice showed resistance to kainic acid-induced
eizures; resistance was diminished in Bad−/−, Kir6.2−/− mice. The
pen probability of single KATP channels was increased in Bad-
eﬁcient neurons, compared to wild types.
Gene expression changes can directly inﬂuence phenotypic
raits; a major inﬂuence on gene expression is genetic variation (Fu
t al., 2012; Grundberg et al., 2010; Williams et al., 2007). It there-
ore seems possible that individual genetic variation inﬂuences the
fﬁcacy of KDT on seizure control. We  hypothesised that variants
n KCNJ11 and BAD may  inﬂuence response to KDT in humans.
aterials and methods
thics and recruitment
The project gained ethical approval through relevant ethics
ommittees or institutional review boards. Written informed con-
ent was obtained from all study participants or from their parents
n the case of minors or adults with intellectual disability.
Participants were recruited from April 2011–December 2012
rom the following sites: Great Ormond Street Hospital for Chil-
ren, London; National Hospital for Neurology and Neurosurgery,
ondon; Evelina Children’s Hospital, London; St George’s Hospi-
al, London; Young Epilepsy (including Matthew’s Friends clinics
or Ketogenic Dietary Therapies), Surrey; Birmingham Children’s
ospital, Birmingham; Addenbrooke’s Hospital, Cambridge; Alder
ey Children’s Hospital, Liverpool; Bristol Royal Hospital for Sick
hildren, Bristol, all in the UK; The Royal Children’s Hospital, Mel-
ourne, Australia; Austin Health, Melbourne, Australia. KCNJ11
equencing data were received from patients from Massachusetts
eneral Hospital, in collaboration with Harvard Medical School,
oston, USA.
Criteria for study inclusion were: individuals aged ≥3 months
ho were either following KDT or who had followed KDT in the pastor epilepsy. Exclusion criteria were: individuals who  discontinued
DT before the 3-month point due to lack of tolerability (those who
iscontinued KDT before the 3-month point due to lack of response
r seizure increase were included), individuals with known glucosesearch 118 (2015) 22–28 23
transporter type 1 deﬁciency syndrome, pyruvate dehydrogenase
complex deﬁciency or known to have other metabolic disorders,
and individuals with progressive myoclonic epilepsies or other pro-
gressive neurological diseases.
In the UK clinics, all eligible for recruitment were invited to
participate. The majority of Australian participants were recruited
prospectively.
Phenotypic data collection
All underwent electroclinical phenotyping to establish seizure
type and epilepsy syndrome. This involved medical history, seizure
semiology, examination and review of EEG and imaging stud-
ies. Demographic data were obtained from medical records. The
proforma used to collect phenotypic information is given in Sup-
plementary Material. Apart from KDT response, detailed clinical
data were not available for cases from Boston.
KDT response was deﬁned in terms of seizure frequency. In 121
cases, response was determined prospectively and in 125 cases
it was  retrospective Response was  estimated in 28 day epochs
prior to starting the diet (baseline) and prior to 3-month follow-
up after the start of KDT. Clinic letters and seizure diaries, where
already used as part of clinical monitoring (in 35 [11.6%] patients),
were used to estimate seizure frequency at each time point. The
calculation used to determine percentage reduction in seizure fre-
quency was: [(a − b)/a] × 100, where a = number of seizures in the
28 days prior to KDT initiation; b = number of seizures in the 28
days preceding the 3-month point (three months since KDT was
started). A case/control study design was adopted. Those with ≥50%
seizure reduction were classiﬁed as ‘responders’; those with <50%
seizure reduction were ‘non-responders’. Seizure freedom achieved
at any follow-up point was  also documented. All cases received
from Boston had diet response classiﬁed at the 3-month point.
For individuals with demographic data available, the effect of
various factors on KDT response was  assessed by logistic regression.
Statistics were performed in R (R: A Language and Environment
for Statistical Computing, Vienna, Austria). To avoid the inﬂated
likelihood of Type I error when testing multiple hypotheses, a
Bonferroni-corrected signiﬁcance threshold was applied.
Genotypic data collection
DNA was extracted from venous blood using Autogen (AutoGen
Inc, Hollister, Massachusetts, USA), Fujiﬁlm (FUJIFILM Corporation,
Tokyo, Japan) or QiaAmp Blood Maxi kits (Qiagen GmbH, Hilden,
Germany).
KCNJ11 and BAD Sanger sequencing was undertaken in a
clinically-accredited laboratory at the Royal Devon & Exeter Hos-
pital. Exon 1 of KCNJ11 was ampliﬁed in three fragments, and the
three exons in BAD were ampliﬁed using M13  tailed PCR primers
(primers on request). Sequencing was  performed using a Big Dye
Terminator Cycler Sequencing Kit (Applied Biosystems, Warring-
ton, UK) according to manufacturer’s instructions. Reactions were
analysed on an ABI 3130 Capillary sequencer (Applied Biosystems,
Warrington, UK) and sequences were compared to the published
sequence (KCNJ11: NM 000525; BAD: NM 004322.3) using Muta-
tion Surveyor v.4.0.6 (SoftGenetics, Pennsylvania, US). Identiﬁed
variants were checked for known mutations (Flanagan et al., 2009).
Common single nucleotide polymorphisms (SNPs) were identi-
ﬁed using public variant databases (dbSNP http://www.ncbi.nlm.
nih.gov/SNP/, 1000 Genomes http://www.1000genomes.org/ and
Exome Variant Server http://evs.gs.washington.edu/EVS/).KCNJ11 sequencing results were also received from Boston.
The full KCNJ11 gene had been sequenced bi-directionally using
three 500–600 bp amplicons with published primers (Inoue et al.,
1997). Sequencing was  performed using an ABI 377 machine (PE
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iosystems, NYSE:PEB) with Big Dye terminator chemistries (PE
iosystems, NYSE:PEB). Sequence traces were analysed using the
AP4 program of the Staden package (http://www.mrc-lmb.cam.
c.uk/pubseq).
ower calculations
Power calculations were conducted using PGA Power Calcula-
or (Menashe et al., 2008). An alpha level according to the effective
umber of tests was used (two phenotypes and seven SNPs were
ffectively tested for in association analyses—two SNPs were in high
inkage disequilibrium). As there is no naturally-existing ketogenic
iet (or indeed sustained calorie restriction, at least in Europeans),
isease (or trait) prevalence is hard to gauge. The estimated preva-
ence of treatment-resistant epilepsy, the usual subject population
onsidered for KDT, was therefore used: a disease prevalence of
pilepsy of 0.5% was used, as in other studies (Kasperaviciute et al.,
010), of which ∼35% are thought to be treatment-resistant. The
enetic architecture of response is unknown and so power calcula-
ions were performed using co-dominant, dominant and recessive
enetrance models.
As shown in Fig. 1, with a sample size of 303 (as used in the
CNJ11 analysis), variants with a minor allele frequency (MAF)
f approximately 0.05 and a relative risk of 3 could be detected
ith 80% power, assuming a dominant or co-dominant penetrance
odel; assuming a recessive penetrance model, the variant MAF
ould have to be at least 0.3 if the variant had a relative risk of
pproximately 3.
ssociation analyses
The following quality control ﬁltering was undertaken: individ-
als were excluded for missing genotype rates >2% and excessive
dentity-by-descent estimates indicating genotypic relatedness
Pi-hat [proportion of identity-by-descent] score >0.4, calculated
rom genome-wide SNP data, which were available for 243 indi-
iduals); SNPs with deviation from Hardy Weinberg equilibrium,
-value <1 × 10−6, or missing rates >2%, were excluded (cases
ig. 1. Detectable relative risk and disease allele frequency curves for a cohort of 303 peo
26  cases and control:case ratio of 1.4 (assuming response as ≥ 50% seizure reduction).search 118 (2015) 22–28
from Boston were analysed separately, as these did not have BAD
sequencing data).
Fisher’s exact test for allelic association was  conducted in PLINK
(http://pngu.mgh.harvard.edu) (Purcell et al., 2007) for KCNJ11 and
BAD variants with MAF  > 0.01. Two response phenotypes were
examined: one, with response deﬁned as ≥50% seizure reduction at
3-month follow-up and another, with response deﬁned as seizure
freedom at 3-month follow-up.
The Cochran–Mantel–Haenszel (CMH) test was also conducted
to correct for population stratiﬁcation. Each cluster was  set as
an ethnic group, which was  self-reported by participants as
genome-wide SNP data were not available for all individuals. The
self-reported ethnicity clusters were: Caucasian (including Aus-
tralian and American Caucasians, n = 251), African (n = 5), Middle
Eastern (n = 6), Central/South Asian (n = 14), East Asian (n = 2), Black
and Caucasian mix  (n = 19), East Asian and Caucasian mix (n = 3),
South Asian and Caucasian (n = 2) and South American (n = 1).
Unadjusted p-values were corrected using the permutation pro-
cedure (100,000 permutations).
Response to KDT in individuals with rare (MAF < 0.01) variants
in KCNJ11 and BAD was evaluated.
The predicted functional impact of variants with MAF  > 0.01
in this cohort was obtained from various algorithms using wAN-
NOVAR (http://wannovar.usc.edu) (Chang and Wang, 2012):
SIFT (Sorting Intolerant From Tolerant) (Ng and Henikoff, 2003),
PolyPhen2 (Polymorphism Phenotyping v2) (Adzhubei et al.,
2010), LRT (likelihood ratio test) (Chun and Fay, 2009), Mutation
Taster (Schwarz et al., 2010) and GERP++ (Genomic Evolutionary
Rate Proﬁling) (Davydov et al., 2010). These scores were only
available for non-synonymous variants. GERP++ scores for syn-
onymous variants were obtained from National Heart, Lung, and
Blood Institute (NHLBI) Exome Variant Server, NHLBI GO Exome
Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS).
Variants were also looked up in Phenotype–Genotype Integrator
(http://www.ncbi.nlm.nih.gov/gap/phegeni), The Human Gene
Mutation Database (http://www.hgmd.cf.ac.uk) (Stenson et al.,
2014) and NCBI (National Center for Biotechnology Information)
Variation Viewer (www.ncbi.nlm.nih.gov/sites/varvu) to obtain
information regarding human phenotypic-genotypic associations
ple, with 80% power, assuming a disease prevalence of 0.00175, an alpha of 0.004,
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nd functional class of the variants, and in dbSNP (http://www.
cbi.nlm.nih.gov/SNP/) to obtain MAF  information.
The predicted functional impact of variants with MAF  < 0.01 not
resent in dbSNP was determined from Alamut reports (v2.2, Inter-
ctive Biosoftware LLC, Rouen, France): function class, SIFT score,
ucleotide and amino acid conservation, and Mutation Taster score.
ariants not present in dbSNP were also sought in the Exome Aggre-
ation Consortium Browser (ExAC, Cambridge, MA  (URL: http://
xac.broadinstitute.org) [December 2014 accessed]).
The predicted functional impact of variants with MAF  < 0.01
resent in dbSNP was obtained from various algorithms using wAN-
OVAR.
esults
ohort demographics
Two individuals were excluded because 3-month KDT response
ata were not available; two further individuals were excluded
ue to lack of KCNJ11 and BAD sequencing data. 246 individuals
ad KCNJ11 and BAD sequencing data and KDT response data avail-
ble. The demographic characteristics of these 246 participants are
ummarised in Table 1.
A further 57 individuals from Boston had KCNJ11 sequencing
esults and KDT response data available (KCNJ11 sequencing data
able 1
ohort clinical data (for cases with diet response data, n = 246).
Gender Male n = 129 (52%)
Female n = 117 (48%)
Age at seizure onset (years)
median (IQR)
0.67 (0.2–2) (unknown for 1 case)
Age  at diet onset (years)
median (IQR)
5.70 (3.2–9.9)
Cause of
epilepsy*
Genetic n = 30 (12.2%)
Structural-metabolic n = 70 (28.5%)
Unknown cause n = 146 (59.3%)
Epilepsy syndrome* Dravet syndrome/severe myoclonic
epilepsy of infancy n = 15 (6.1%);
Lennox–Gastaut syndrome/LGS-spectrum
n = 11 (4.5%); childhood absence epilepsy
n = 3 (1.2%); juvenile myoclonic epilepsy
n  = 2 (0.8%); juvenile absence epilepsy n = 3
(1.2%); epilepsy with myoclonic atonic
(astatic) seizures (Doose syndrome) n = 14
(5.7%); epilepsy with myoclonic absences
n  = 1 (0.4%); epilepsy with myoclonic
atonic seizures and myoclonic absences
n = 2 (0.8%); myoclonic epilepsy
(unspeciﬁed) n = 7 (2.8%); epilepsy of
infancy with migrating focal seizures n = 3
(1.2%); ohtahara syndrome n = 1 (0.4%);
west syndrome n = 15 (6.1%); undiagnosed
n = 169 (68.7%)
Number of AEDs at diet
onset mean [95% CI]
2.33 [0.98–3.69]
Number of failed AEDs
prior to diet onset mean
[95% CI]
6.66 [4.84–8.49] (unknown for 3 cases)
Diet  type (at 3-month
point)**
Classical Ketogenic diet n = 161 (65.4%)
Medium Chain Triglyceride Ketogenic Diet
n = 47 (19.1%)
Modiﬁed Atkins Diet n = 38 (15.4%)
Feed Oral n = 167 (67.9%)
Gastrostomy/naso-gastric tube n = 63
(25.6%)
Oral and tube n = 16 (6.5%)
* Cause of epilepsy (genetic, structural/metabolic, unknown) and epilepsy syn-
romes have been classiﬁed according to Berg et al. (2010).
** No patients were following the Low Glycaemic Index Treatment, as this was
ot offered as a diet option at the study sites. If a patient transitioned to a different
iet type before the 3-month point, the new/second diet type was  considered this
ndividual’s ‘diet type’.search 118 (2015) 22–28 25
were available for 58 individuals from Boston but response data
were not available for one of these individuals). 176/303(58%) were
responders at the 3-month point; 22/303(7%) were seizure-free. No
demographic factor was signiﬁcantly associated with KDT response
at 3-month follow-up, for either response phenotype (see Supple-
mentary Table 1). A Bonferroni-corrected signiﬁcance threshold
was set, based on an alpha of 0.05 and 28 tests (corrected thresh-
old = 0.002; two phenotypes and 14 demographic factors).
Association analyses
Six SNPs in KCNJ11 and two  in BAD had a MAF  of >0.01 in our
cohort and so were used in the association analyses; all these vari-
ants were previously-reported in dbSNP and ExAC. These variants
are listed in Supplementary Table 2, with their predicted functional
impact. Two  variants in KCNJ11,  rs5215 and rs5219, were in high
LD (r2 = 0.9933 in our cohort, calculated using PLINK) and present
with the same haplotype in 166 individuals.
No SNPs were removed due to deviation from Hardy Weinberg
equilibrium or missingness rates. 243 individuals had genome-
wide SNP data available; one pair of siblings was  removed due
to relatedness. KCNJ11 and BAD sequencing failed in three sub-
jects. 176 responders and 127 non-responders were included in
the KCNJ11 analysis; 126 responders and 120 non-responders were
included in the BAD analysis.
None of the permutation-corrected p-values, from Fisher or
CMH  tests, with either KDT response phenotype, reached the formal
threshold for a signiﬁcant association (see Tables 2 and 3). rs5216
in KCNJ11 had an uncorrected p-value (p = 0.019) that surpassed
the threshold for suggestive signiﬁcance (1/number of tests), in the
≥50% seizure reduction response phenotype analysis.
Variants with MAF < 0.01
Eight variants in KCNJ11 (all of which were previously reported
in dbSNP or ExAC) and seven in BAD (of which three were previ-
ously reported in dbSNP or ExAC) had MAF  < 0.01 in our cohort. KDT
response in cases with these variants, with the predicted functional
impact of these variants, is given in Supplementary Table 3.
Five variants have a predicted impact on protein structure.
NM 00525.3:c.[451G > A];[=], p.Val151Met in KCNJ11 encodes a
highly-conserved amino acid (conserved up to Tetraodon [puffer-
ﬁsh]), has a deleterious SIFT classiﬁcation and is classiﬁed as
disease-causing by Mutation Taster. This variant was found in one
non-responder. The missense variant rs41282930 in KCNJ11 also
has a predicted functional impact and was present in six individ-
uals with a range of responses to KDT. NM 00525.3:c.[817A > G];[=]
p.Ser273Gly in KCNJ11 (present in one partial responder) and
NM 004322.3:c. [226T > A];[=] p.Tyr76Asn in BAD (present in one
responder and one non-responder) had deleterious SIFT classiﬁca-
tions but were not predicted to be damaging by all other algorithms.
NM 004322.3:c.[142G > A];[=] p.Ala48Thr in BAD (present in one
non-responder) was  not predicted to be damaging by either SIFT or
Mutation Taster and was  not highly conserved.
Discussion
We evaluated the effect of variation in candidate genes KCNJ11
and BAD on response to KDT. No signiﬁcant results were obtained
from our association studies, with either of our response pheno-
types. With a sample size of 303, we had 80% power to detect
associations of variants with a MAF  of ≥0.05 and relative risk of
≥3, depending on the genetic model assumed. Variants in KCNJ11
or BAD may  have a smaller effect on KDT response, which we did not
have power to detect. However, such effect sizes are unlikely to be
clinically relevant when attempting to predict response to dietary
26 N.E. Schoeler et al. / Epilepsy Research 118 (2015) 22–28
Table 2
Results of association analyses: common and intermediate variation in KCNJ11 and BAD in responders (≥50% seizure reduction or seizure freedom at 3-month follow-up)
and  non-responders of KDT: n = 303 for KCNJ11 and n = 246 for BAD.
With KDT response deﬁned as ≥50% seizure reduction at 3-month follow-up
Gene SNP rs
number
Location (build
37/hg19)
Minor allele (in
ketogenic diet
cohort)
Frequency of
minor allele in
non-responders
Frequency of
minor allele in
responders
Unadjusted
p-value
Odds ratio [95%CI] p-Value
(100,000
permutations)
KCNJ11 rs8175351 11: 17,408,496 A 0.02756 0.02557 1 1.08 [0.3969–2.939] 1
rs1800467 11: 17,408,831 G 0.07087 0.04261 0.1481 1.714 [0.8466–3.468] 0.6355
rs5219 11: 17,409,572 A 0.3268 0.3381 0.7938 0.9504 [0.6745–1.339] 0.9997
rs5215 11: 17,408,630 A 0.3268 0.3381 0.7938 0.9504 [0.6745–1.339] 0.9997
rs5218 11: 17,409,069 T 0.248 0.304 0.1429 0.7552 [0.5247–1.087] 0.6122
rs5216 11: 17,408,838 G 0.007874 0.03977 0.01872 0.1916 [0.04316–0.8507] 0.132
BAD rs34882006 11: 64,051,823 A 0.05 0.03175 0.3645 1.605 [0.6445–3.998] 0.9406
rs2286615 11: 64,039,175 T 0.1125 0.1706 0.07133 0.6161 [0.3671–1.034] 0.362
With  KDT response deﬁned as seizure freedom at 3-month follow-up
KCNJ11 rs8175351 11: 17,408,496 A 0.02491 0.04545 0.326 0.5365 [0.118–2.439] 0.9043
rs1800467 11: 17,408,831 G 0.05872 0 0.1594 n/a 0.6116
rs5219 11: 17,409,572 A 0.3399 0.25 0.2489 1.544 [0.7636–3.124] 0.7493
rs5215 11: 17,408,630 A 0.3399 0.25 0.2489 1.544 [0.7636–3.124] 0.7493
rs5218 11: 17,409,069 T 0.2776 0.3182 0.6018 0.8234 [0.4253–1.594] 0.9856
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ars5216 11: 17,408,838 G 0.02847
BAD rs34882006 11: 64,051,823 A 0.04202 
rs2286615 11: 64,039,175 T 0.145 
herapies, though variants with smaller effect sizes may  still cast
ight on the mechanisms of action of KDT.
rs5216 in KCNJ11 merits possible further investigation as it
eached suggestive signiﬁcance in the ≥50% seizure reduction
henotype analysis. In pancreatic  cells, the binding of adenine
ucleotides to the Kir6.2 pore closes the channel; variants affect-
ng this subunit could inﬂuence the open-channel probability and
lter cell excitability (Babenko et al., 2006). Considering the ‘KATP-
lycolysis hypothesis’ (Yellen, 2008), if rs5216 were to alter KATP
pen-channel probability in the brain, this may  affect the extent
o which KDT depress neuronal excitability. The functional con-
equences of rs5216 on KATP channel activity are unknown. It is
ocated in a conserved region and is rare in the general popula-
ion, indicating that it may  inﬂuence gene/protein function and
ay  be damaging (Liu and Kumar, 2013). rs5216, however, is a
ynonymous variant and is predicted by SIFT to be tolerated.
The previously-unreported variants and those SNPs with
AF < 0.01 in this cohort are unlikely to be important for most peo-
le following KDTs. They are not variants that inﬂuence response to
DT shared across patients; most variants were only present in one
r two individuals. The possibility cannot be discarded that other,
are variants in KCNJ11 or BAD, not found in this cohort, may  play
able 3
esults of association analyses: common and intermediate variation in KCNJ11 and BAD 
nd  non-responders of KDT, including ethnicity as a covariate: n = 303 for KCNJ11 and n =
With KDT response deﬁned as ≥50% seizure reduction at 3-month follow-up
Gene SNP rs number Unadjusted p-value 
KCNJ11 rs8175351 0.9842 
rs1800467 0.1668 
rs5219 and rs5215 0.9602 
rs5218 0.1712 
rs5216 0.01847 
BAD rs34882006 0.3133 
rs2286615 0.07559 
With  KDT response deﬁned as seizure freedom at 3-month follow-up
KCNJ11 rs8175351 0.2264 
rs1800467 0.1063 
rs5219 and rs5215 0.07526 
rs5218 0.4768 
rs5216 0.2451 
BAD rs34882006 0.4203 
rs2286615 0.4221 0 0.6207 n/a 0.9962
0 1 n/a 1
0.0625 0.7126 2.543 [0.3306–19.56] 0.9986
a minor role in response to KDT. Deep resequencing with applica-
tion of stringent genotype call probabilities may  be the only way
to identify the full extent of rare genetic variation in an individual
(Coventry et al., 2010).
This study has limitations. Due to the nature of dietary interven-
tions such as KDT and the limited available of KDT in the UK, the
sample size in this study is numerically small. Approximately 250
people were following the KD for epilepsy in the UK  in 2011–2012
and 264 started the KD in 2012–2013 (personal communication,
Katherine Lord, Head of Nutrition and Dietetics at Southmead
Hospital and chairperson of Ketogenic Diet Professional Advisory
Group, UK). Further international collaboration would be needed
to obtain a larger cohort size. The time-points at which response
is calculated also inﬂuence results. For many people with epilepsy,
‘responder’ or ‘non-responder’ status to KDT is known by the 3-
month point, but it may  take longer to categorise response for
others, for example, those with seizure clusters. Alternative pro-
cedures to estimate response may  need to be explored. p-Values
were largely unaffected when including ethnicity as a covariate;
whilst genetic inﬂuence on response to KDT might genuinely not
be confounded by population stratiﬁcation, it is difﬁcult to be cer-
tain with our small number of non-European participants. In future
in responders (≥50% seizure reduction or seizure freedom at 3-month follow-up)
 246 for BAD.
Odds ratio [95%CI] p-Value (100,000
permutations)
1.01 [0.369–2.766] 1
1.656 [0.8072–3.396] 0.7343
1.009 [0.7099–1.434] 1
0.7728 [0.5342–1.118] 0.7514
0.1975 [0.0444–0.8784] 0.1318
1.598 [0.6387–3.997] 0.9329
0.6219 [0.3682–1.05] 0.4272
0.3954 [0.08367–1.869] 0.8182
n/a 0.5337
1.977 [0.9215–4.241] 0.377
0.7799 [0.3936–1.545] 0.9951
n/a 0.8889
n/a 0.9835
2.274 [0.2915–17.73] 0.9843
sy Re
s
r
w
M
w
p
w
n
a
C
K
f
r
t
K
T
a
C
N
w
(
D
a
b
J
g
t
w
w
r
E
N
s
r
A
t
a
d
O
d
H
(
C
t
H
(
r
C
t
f
H
r
D
(
dN.E. Schoeler et al. / Epilep
tudies, the issue of ethnicity and response to KDT should not be dis-
egarded, as certain variants may  be more relevant in populations
ith a more recent or longer history of survival through starvation.
ost such populations, however, will not have epilepsy services
ith capacity for KDT, if indeed any treatment is available.
Our heterogeneous cohort is typical of individuals with com-
lex epilepsy who commence KDT. Conducting association studies
ith narrower phenotypes, where patients are in more homoge-
ous groups, for example, by epilepsy cause or syndrome, may  be
n option for future analyses.
onclusion
We  have shown that common variants in the candidate genes
CNJ11 and BAD are not associated with response to KDT at 3-month
ollow-up. Associations from variants with a smaller effect size or
are variants may  be detected with a larger sample size. It remains
o be seen whether variants in other genes inﬂuence response to
DT. An unbiased approach across the genome or exome is needed.
his may  allow us to identify biological pathways not previously
ssociated with response to KDT (Minihane, 2013).
onﬂict of interest statement
This study was partly funded by the Wellcome Trust (084730).
ES is supported by a UCL Impact Studentship in conjunction
ith Epilepsy Society. MM is supported by Epilepsy Research UK
F1206). JWS  receives research support from Epilepsy Society, the
r. Marvin Weil Epilepsy Research Fund, Eisai, GSK, WHO, EU FP7
nd the National Institutes of Health (NIH), and has been consulted
y and received fees for lectures from GSK, Eisai and UCB Pharma.
HC has received funds to the department for research into the keto-
enic diet from Vitaﬂo. Honoraria for speaking have also been made
o the department on her behalf from Nutricia. JHC and IS have
ritten a cookery book ‘Ketocooking’, funds from the sale of which
ill be donated to their respective departments. SMS  receives
esearch support from Epilepsy Society, The Wellcome Trust, The
uropean Commission, Dravet Syndrome UK, Epilepsy Action, MRC,
IH and The Katy Baggott Foundation and has received research
upport/fees from lectures from Eisai, GSK and UCB Pharma. The
emaining authors have no conﬂicts of interest.
cknowledgements
We thank the patients and their families for participating in
he research. The authors are grateful to the following clinicians
nd staff that assisted with recruitment and provided phenotypic
etails: C. Eltze, M.  Sewell, C. Fitzachary and G. Fitzsimmons (Great
rmond Street Hospital, London); R. Williams, M-A. Leung, T. Ran-
all, L. Alford, A. Tomalin and E. Hughes (Evelina London Children’s
ospital, London); H. Chan, C. Ellerton, C. Maritz and R. Lachmann
National Hospital for Neurology and Neurosurgery, London); B.
oncannon, S. Philip and V. Hopkins (Birmingham Children’s Hospi-
al, Birmingham); P. Fallon, O. Stone and N. Dos Santos (St George’s
ospital, London); V. Aldridge, E. Neal, T. Stein and A. Desurkar
Matthew’s Friends clinics for Ketogenic Dietary Therapies, Sur-
ey); H. Champion, A. Parker and A. Maw  (Addenbrooke’s Hospital,
ambridge); R. Kneen and B. Evans (Alder Hey Children’s Hospi-
al, Liverpool); M.  Dunlop and H. Edwards (Bristol Royal Hospital
or Sick Children, Bristol); J. Bicknell-Royle (The Royal Children’s
ospital, Melbourne, Australia); A. Tostevin (UCL Institute of Neu-
ology, London). We  also thank A. Smith and N. Vincent (Royal
evon & Exeter Hospital), Raquel Duran Ogalla and Jamie Toombs
UCL Institute of Neurology, London) for their assistance with can-
idate gene sequencing. The authors would like to thank the Exomesearch 118 (2015) 22–28 27
Aggregation Consortium and the groups that provided exome vari-
ant data for comparison. A full list of contributing groups can be
found at http://exac.broadinstitute.org/about.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.eplepsyres.2015.
10.003.
References
Adzhubei, I.A., Schmidt, S., Peshkin, L., et al., 2010. A method and server for
predicting damaging missense mutations. Nat. Methods 7, 248–249.
Babenko, A.P., Polak, M.,  Cave, H., et al., 2006. Activating mutations in the ABCC8
gene in neonatal diabetes mellitus. N. Engl. J. Med. 355, 456–466.
Berg, A.T., Berkovic, S.F., Brodie, M.J., et al., 2010. Revised terminology and concepts
for  organization of seizures and epilepsies: report of the ILAE Commission on
Classiﬁcation and Terminology, 2005–2009. Epilepsia 51, 676–685.
Chang, X., Wang, K., 2012. wANNOVAR: annotating genetic variants for personal
genomes via the web. J. Med. Genet. 49, 433–436.
Chun, S., Fay, J.C., 2009. Identiﬁcation of deleterious mutations within three human
genomes. Genome Res. 19, 1553–1561.
Coventry, A., Bull-Otterson, L.M., Liu, X., et al., 2010. Deep resequencing reveals
excess rare recent variants consistent with explosive population growth. Nat.
Commun. 1, 131.
Danial, N.N., Gramm, C.F., Scorrano, L., et al., 2003. BAD and glucokinase reside in a
mitochondrial complex that integrates glycolysis and apoptosis. Nature 424,
952–956.
Danial, N.N., Walensky, L.D., Zhang, C.Y., et al., 2008. Dual role of proapoptotic BAD
in  insulin secretion and beta cell survival. Nat. Med. 14, 144–153.
Davydov, E.V., Goode, D.L., Sirota, M., et al., 2010. Identifying a high fraction of the
human genome to be under selective constraint using GERP++. PLoS Comput.
Biol. 6, e1001025.
Dutton, S.B.B., Escayg, A., 2008. Genetic inﬂuences on ketogenic diet efﬁcacy.
Epilepsia 49 (Suppl. 8), 67–69.
Flanagan, S.E., Clauin, S., Bellanne-Chantelot, C., et al., 2009. Update of mutations in
the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2
(KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and
hyperinsulinism. Hum. Mutat. 30, 170–180.
Fu, J., Wolfs, M.G., Deelen, P., et al., 2012. Unraveling the regulatory mechanisms
underlying tissue-dependent genetic variation of gene expression. PLoS Genet.
8,  e1002431.
Giménez-Cassina, A., Martínez-Franc¸ ois, Juan R., Fisher, Jill K., et al., 2012.
BAD-dependent regulation of fuel metabolism and KATP channel activity
confers resistance to epileptic seizures. Neuron 74, 719–730.
Grundberg, E., Kwan, T., Pastinen, T.M., 2010. Analysis of the impact of genetic
variation on human gene expression. Methods Mol. Biol. 628, 321–339.
Henderson, C.B., Filloux, F.M., Alder, S.C., et al., 2006. Efﬁcacy of the ketogenic diet
as  a treatment option for epilepsy: meta-analysis. J. Child Neurol. 21, 193–198.
Inoue, H., Ferrer, J., Warren-Perry, M.,  et al., 1997. Sequence variants in the
pancreatic islet beta-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene:
identiﬁcation and lack of role in Caucasian patients with NIDDM. Diabetes 46,
502–507.
Kasperaviciute, D., Catarino, C.B., Heinzen, E.L., et al., 2010. Common genetic
variation and susceptibility to partial epilepsies: a genome-wide association
study. Brain 133, 2136–2147.
Keene, D.L., 2006. A systematic review of the use of the ketogenic diet in childhood
epilepsy. Pediatr. Neurol. 35, 1–5.
Kossoff, E.H., Zupec-Kania, B.A., Amark, P.E., et al., 2009. Optimal clinical
management of children receiving the ketogenic diet: recommendations of the
International Ketogenic Diet Study Group. Epilepsia 50, 304–317.
Liu, L., Kumar, S., 2013. Evolutionary balancing is critical for correctly forecasting
disease-associated amino acid variants. Mol. Biol. Evol. 30, 1252–1257.
Menashe, I., Rosenberg, P.S., Chen, B.E., 2008. PGA: power calculator for
case-control genetic association analyses. BMC  Genet. 9, 36.
Minihane, A.M., 2013. The genetic contribution to disease risk and variability in
response to diet: where is the hidden heritability? Proc. Nutr. Soc. 72, 40–47.
Nangia, S., Caraballo, R.H., Kang, H.-C., et al., 2012. Is the ketogenic diet effective in
speciﬁc epilepsy syndromes? Epilepsy Res. 100, 252–257.
Neal, E.G., Chaffe, H., Schwartz, R.H., et al., 2008. The ketogenic diet for the
treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol.
7,  500–506.
Ng, P.C., Henikoff, S., 2003. SIFT: predicting amino acid changes that affect protein
function. Nucleic Acids Res. 31, 3812–3814.Payne, N.E., Cross, J.H., Sander, J.W., et al., 2011. The ketogenic and related diets in
adolescents and adults—a review. Epilepsia 52, 1941–1948.
Purcell, S., Neale, B., Todd-Brown, K., et al., 2007. PLINK: a tool set for
whole-genome association and population-based linkage analyses. Am.  J. Hum.
Genet. 81, 559–575.
2 sy Re
S
S
S8 N.E. Schoeler et al. / Epilep
choeler, N.E., Cross, J.H., Sander, J.W., et al., 2013. Can we  predict a favourable
response to Ketogenic Diet Therapies for drug-resistant epilepsy? Epilepsy Res.
106, 1–16.chwarz, J.M., Rodelsperger, C., Schuelke, M.,  et al., 2010. MutationTaster evaluates
disease-causing potential of sequence alterations. Nat. Methods 7,
575–576.
tenson, P.D., Mort, M., Ball, E.V., et al., 2014. The Human Gene Mutation Database:
building a comprehensive mutation repository for clinical and molecularsearch 118 (2015) 22–28
genetics, diagnostic testing and personalized genomic medicine. Hum. Genet.
133, 1–9.
Thammongkol, S., Vears, D.F., Bicknell-Royle, J., et al., 2012. Efﬁcacy of the
ketogenic diet: which epilepsies respond? Epilepsia 53, e55–e59.
Williams, R.B., Chan, E.K., Cowley, M.J., et al., 2007. The inﬂuence of genetic
variation on gene expression. Genome Res. 17, 1707–1716.
Yellen, G., 2008. Ketone bodies, glycolysis, and KATP channels in the mechanism of
the ketogenic diet. Epilepsia 49 (Suppl. 8), 80–82.
